“Given the notable interest from global and specialty pharmaceutical companies that we have received following recent Brilacidin-OM data releases, we continue to carefully assess all of our potential alliance opportunities—toward cementing the best pathway forward,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “The expedient advancement of Brilacidin-OM into later clinical development is a priority, as is the broader expansion of the complete Brilacidin Franchise.”
Clearly anyone with a 5th grade reading level understands that the ball is in IP's court. The requirements are for a world-wide partner not only for BOM but also for the entire B franchise. Nothing less will do.
Given the overall success and potential of Brilicidan, this is exactly as it should be.
Market Data 
Markets 
AI
